Howard Ilivicky, MD
Psychiatry · Saint Charles, MONPI 1093711152
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,906 of the $24,000 with a category attached, or 66.3%. 36 manufacturers reported payments, led by Boehringer Ingelheim at 35.4% of the total. Reporting peaked in 2023 at $9,803 and has fallen 83.1% since, to $1,661 in 2025. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 968 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$8K
- Sunovion Pharmaceuticals Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $9K from 30 others
Across 318 payments — averaging $6554.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$799K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$533K
- Boehringer Ingelheim$344K
- Sage Therapeutics, LLC$177K
- Alkermes, Inc.$121K
- Purdue Pharma L.p.$37K
- plus $74K from 8 others
What the payments were for
- Consulting fees$5,78524%
- Travel & lodging$2,2739%
- Food & beverage$15,90666%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,000 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 30 | $343,017 |
| IngrezzaValbenazine Tosylate | 33 | $272,046 |
| Tetrabenazine | 12 | $166,038 |
| VraylarCariprazine Hcl | 51 | $88,138 |
| Invega SustennaPaliperidone Palmitate | 21 | $68,656 |
| Risperdal ConstaRisperidone Microspheres | 28 | $57,038 |
| RexultiBrexpiprazole | 20 | $45,849 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $31,148 |
| TrintellixVortioxetine Hydrobromide | 31 | $25,549 |
| Divalproex Sodium ErDivalproex Sodium | 134 | $12,319 |
| Aripiprazole | 120 | $8,829 |
| Atomoxetine Hcl | 43 | $8,395 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 107 | $7,657 |
| FetzimaLevomilnacipran Hcl | 13 | $7,426 |
| Bupropion XlBupropion Hcl | 313 | $7,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $871 | $343,01730 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,169 | $272,04633 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Concerta | $553 | $130,94861 claims |
| AbbVieVraylar, Fetzima | $1,409 | $95,56464 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,339 | $45,84920 claims |
| Alkermes, Inc.Lybalvi | $602 | $31,14817 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $808 | $25,54931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Charles
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
- Ahmed TaranissiMexico$343K
- Ravdeep KhanujaPoplar Bluff$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.